logo
Kepler Capital Remains a Hold on Datalogic SPA (0E3C)

Kepler Capital Remains a Hold on Datalogic SPA (0E3C)

Kepler Capital analyst Matteo Bonizzoni maintained a Hold rating on Datalogic SPA (0E3C – Research Report) on May 16 and set a price target of €5.40. The company's shares closed last Friday at €4.58.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Bonizzoni is a 5-star analyst with an average return of 15.1% and a 57.78% success rate.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Datalogic SPA with a €6.35 average price target.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies
Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Business Insider

time15 hours ago

  • Business Insider

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Jefferies lowered the firm's price target on Dassault Systemes (DASTY) to EUR 27 from EUR 28 and keeps an Underperform rating on the shares. The firm says ongoing macro uncertainty means positive surprises are unlikely in the company's Q2. It believes questions over whether Dassault will meet guidance are persist until year-end. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Sarepta price target lowered to $30 from $84 at JPMorgan
Sarepta price target lowered to $30 from $84 at JPMorgan

Business Insider

time16 hours ago

  • Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

Business Insider

time16 hours ago

  • Business Insider

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store